TRAXFirst Tracks Biotherapeutics, Inc.
$16.37
$16.37
$15.3252 weeks$47.80
TRAX in its own filings
Nothing in TRAX's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
9
Events found in the filings · across 84 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 10-Q
- Record starts
- Apr 3, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 11, 2026
- SEC comment-letter activity2 occurrences
- 2026-05-08
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 22, 2026On June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 …Material agreement entered · Form 8-K
- May 14, 2026First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Apr 20, 2026Prior to the Distribution Date, in connection with the Spin-Off, the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the “Spin Agreements”) with AnaptysBio that set forth the principal actions taken or to be taken in connection with the Spin-Off and that …Material agreement entered · Form 8-K
- Apr 3, 2026September 2025, we announced our intention to separate our biopharma operations from our substantial royalty assets to unlock value by creating two publicly traded companies, each with a focused strategy and clear path forward.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry